TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.

Tibotec, Mechelen, Belgium.
Journal of Virology (Impact Factor: 4.65). 11/2005; 79(20):12773-82. DOI: 10.1128/JVI.79.20.12773-12782.2005
Source: PubMed

ABSTRACT TMC125 is a potent new investigational nonnucleoside reverse transcriptase inhibitor (NNRTI) that is active against human immunodeficiency virus type 1 (HIV-1) with resistance to currently licensed NNRTIs. Sequential passage experiments with both wild-type virus and NNRTI-resistant virus were performed to identify mutations selected by TMC125 in vitro. In addition to "classic" selection experiments at a low multiplicity of infection (MOI) with increasing concentrations of inhibitors, experiments at a high MOI with fixed concentrations of inhibitors were performed to ensure a standardized comparison between TMC125 and current NNRTIs. Both low- and high-MOI experiments demonstrated that the development of resistance to TMC125 required multiple mutations which frequently conferred cross-resistance to efavirenz and nevirapine. In high-MOI experiments, 1 muM TMC125 completely inhibited the breakthrough of resistant virus from wild-type and NNRTI-resistant HIV-1, in contrast to efavirenz and nevirapine. Furthermore, breakthrough of virus from site-directed mutant (SDM) SDM-K103N/Y181C occurred at the same time or later with TMC125 as breakthrough from wild-type HIV-1 with efavirenz or nevirapine. The selection experiments identified mutations selected by TMC125 that included known NNRTI-associated mutations L100I, Y181C, G190E, M230L, and Y318F and the novel mutations V179I and V179F. Testing the antiviral activity of TMC125 against a panel of SDMs indicated that the impact of these individual mutations on resistance was highly dependent upon the presence and identity of coexisting mutations. These results demonstrate that TMC125 has a unique profile of activity against NNRTI-resistant virus and possesses a high genetic barrier to the development of resistance in vitro.

Download full-text


Available from: Dirk Jochmans, Jun 23, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Etravirine (ETR) is a non-nucleoside analogue reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to the development of resistance and with potential activity against Human immunodeficiency virus type 1 (HIV-1) strains resistant to first-generation NNRTIs. The objective of this study was to investigate the prevalence of ETR resistance associated mutations (RAMs) in HIV-1 strains isolated from infected individuals failing efavirenz (EFV), as well as to evaluate possible differences in the distribution of ETR RAMs between subtype B and non-B genetic variants. Nucleotide sequences of the protease and partial reverse transcriptase (RT) coding regions of the pol gene of 55 HIV-1 strains isolated from infected individuals failing EFV on regular follow-up at a reference center in Portugal, were retrospectively analyzed. The most prevalent ETR RAMs observed were L100I, V90I, and K101E, with a prevalence of 16.4% (n = 9), 9.1% (n = 5), and 5.5% (n = 3), respectively. Overall, 47.3% (n = 26) of the nucleotide sequences had at least one ETR RAM: 38.2% (n = 21) had one ETR RAM, 7.3% (n = 4) had two ETR RAMs and 1.8% (n = 1) had three ETR RAMs. No statistically significant differences were found in the distribution of ETR RAMs between subtype B and non-B genetic variants. The results demonstrate that ETR rescue therapy is a viable option in treatment-experienced individuals failing EFV and suggests that ETR may be equally useful in HIV-1 infections caused by different genetic variants.
    Journal of Medical Virology 04/2012; 84(4):551-4. DOI:10.1002/jmv.23232 · 2.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Doravirine (DOR, formerly known as MK-1439) is a human immunodeficiency type 1 virus (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI), which is currently in Ph 2b clinical trials. In vitro resistance selection was conducted with DOR, rilpivirine (RPV), and efavirine (EFV) in subtype B virus (MT4-GFP cells) as well as subtypes A and C viruses (MT4-GFP/CCR5 cells) under low multiplicity of infection (moi) conditions in 96-well format. The resistance selection was performed with escalating concentration of the NNRTIs from 1x EC50 to 1000x EC50 in the presence of 10% FBS. In the resistance selection with DOR in subtype B virus, V106A mutant led two mutation pathways followed by the emergence separately of either F227L or L234I. In the resistance selection in subtype A and C viruses, similar mutation development pathways were detected, which V106A or V106M mutant was also the starting virus in the pathways. Mutants that are commonly associated with RPV and EFV in the clinical settings were also identified in this in vitro resistance selection study in subtype B virus, such as E138K and K103N, respectively. The susceptibility of subtype B mutant viruses selected by DOR, RPV, and EFV to NNRTIs was evaluated. Results suggest that mutant viruses selected by DOR are susceptible to RPV and EFV, and mutants selected by RPV and EFV are susceptible to DOR. When the replication capacity of V106A mutant was evaluated versus wild-type (WT) virus, the mutant virus displayed 4-fold reduction in fitness compared with WT virus.
    Antimicrobial Agents and Chemotherapy 11/2014; 59(1). DOI:10.1128/AAC.04201-14 · 4.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 08_BC (CRF08_BC), carrying recombinant reverse transcriptase (RT) gene from subtypes B and C, has recently become highly prevalent in Southern China. As the patient number increases, it is important to characterize the drug resistance mutations of CRF08_BC, especially against widely used antiretrovirals. In this study, clinically isolated virus (2007CNGX-HK), which was confirmed to be CRF08_BC and its sequence was deposited in Genbank (KF312642), was propagated in human peripheral blood mononuclear cells (PBMCs) with increasing concentrations of nevirapine (NVP), efavirenz (EFV) or lamivudine (3TC). Three different resistance patterns led by initial mutations of Y181C, E138G and Y188C were detected after the selection with NVP. Initial mutations, in combination with other previously reported substitutions (K20R, D67N, V90I, K101R/E, V106I/A, V108I, F116L, E138R, A139V, V189I, G190A, D218E, E203K, H221Y, F227L, N348I and T369I) or novel mutations (V8I, S134N, C162Y, L228I, Y232H, E396G and D404N) developed during NVP selection. EFV-associated variations contained two initial mutations (L100I and Y188C) and three other mutations (V106L, F116Y and T139V). Phenotypic analyses showed that E138R, Y181C and G190A contributed high level resistance to NVP, while L100I and V106L significantly reduce virus susceptibility to EFV. Y188C resulted in a 20-fold less sensitive to both NVP and EFV. As expected, M184I alone or with V90I or D67N, decreased 3TC susceptibility by over 1000-fold. Although the mutation profile obtained in culture may be different to the patients, these results may still provide useful information to monitor and optimize the antiretroviral regimens.
    AIDS Research and Human Retroviruses 12/2014; 31(2). DOI:10.1089/AID.2013.0211 · 2.46 Impact Factor